Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children
Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, Anne Schaap-Nutt, Ursula J Buchholz, Alexander C Schmidt, Emmalene J Bartlett, Brian R Murphy, Peter L Collins, Ruth A Karron, Jocelyn San Mateo, Bhagvanji Thumar, Anne Schaap-Nutt, Ursula J Buchholz, Alexander C Schmidt, Emmalene J Bartlett, Brian R Murphy, Peter L Collins
Abstract
We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1-seropositive children, and HPIV-1-seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1-seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1-seronegative children.
Keywords: HPIV-1 vaccine; children; lower respiratory tract illness.
© The Author 2014. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Source: PubMed